Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

OBJECTIVES: The capability of the SARS-CoV-2 Omicron variant to escape immunity conferred by mRNA vaccines has led to the development of Omicron-adapted vaccines. In this study, we aimed to compare the immune response with the ancestral strain and with the BA.1 Omicron variant after administration o...

Descripción completa

Detalles Bibliográficos
Autores principales: Barda, Noam, Lustig, Yaniv, Indenbaum, Victoria, Zibly, Daniel, Joseph, Gili, Asraf, Keren, Weiss-Ottolenghi, Yael, Amit, Sharon, Kliker, Limor, Abd Elkader, Bayan, Ben-Ami, Eytan, Canetti, Michal, Koren, Ravit, Katz-Likvornik, Shiri, Halpern, Osnat, Mendelson, Ella, Doolman, Ram, Harats, Dror, Kreiss, Yitshak, Mandelboim, Michal, Regev-Yochay, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010049/
https://www.ncbi.nlm.nih.gov/pubmed/36921715
http://dx.doi.org/10.1016/j.cmi.2023.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010049/
https://www.ncbi.nlm.nih.gov/pubmed/36921715
http://dx.doi.org/10.1016/j.cmi.2023.03.007

Ejemplares similares